Want to see KR:228760 full AI Analyst Report?
Genomictree, Inc. (228760) Stock Statistics & Valuation Metrics
Total Valuation
Genomictree, Inc. has a market cap or net worth of KRW 244.26B. The enterprise value is KRW 187.37B.
- Market Cap
- KRW 244.26B
- Enterprise Value
- KRW 187.37B
Share Statistics
Genomictree, Inc. has 24,859,201 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 24,859,201
- Owned by Insiders
- ―
- Owned by Institutions
- 0.16%
Financial Efficiency
Genomictree, Inc.’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -9.52%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -9.52%
- Return on Capital Employed (ROCE)
- -0.10
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- ―
- Asset Turnover
- 0.03
- Inventory Turnover
- 13.90
Valuation Ratios
The current PE Ratio of Genomictree, Inc. is -63.16. Genomictree, Inc.’s PEG ratio is -2.22.
- PE Ratio
- -63.16
- PS Ratio
- 135.29
- PB Ratio
- 4.16
- Price to FCF
- -44.60
- Price to Operating Cash Flow
- -58.28
- PEG Ratio
- -2.22
Income Statement
In the last 12 months, Genomictree, Inc. had revenue of 3.76B and earned -8.99B in profits. Earnings per share was -374.27.
- Revenue
- 3.76B
- Gross Profit
- 73.36M
- Operating Income
- -11.30B
- Pretax Income
- -9.11B
- Net Income
- -8.99B
- EBITDA
- -10.28B
- Earnings Per Share (EPS)
- -374.27
Cash Flow
In the last 12 months, operating cash flow was -8.80B and capital expenditures -223.61M, giving a free cash flow of -11.60B billion.
- Operating Cash Flow
- -8.80B
- Free Cash Flow
- -11.60B
- Free Cash Flow per Share
- -477.31
Dividends & Yields
Genomictree, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.24%
- Earnings Yield
- -1.56%
Stock Price Statistics
- Beta
- 0.10
- 52-Week Price Change
- -49.31%
- 50-Day Moving Average
- 10806.40
- 200-Day Moving Average
- 14763.15
- Relative Strength Index (RSI)
- 46.21
- Average Volume (3m)
- 103.12K
Important Dates
Genomictree, Inc. upcoming earnings date is Nov 06, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 06, 2026
- Ex-Dividend Date
- ―
Financial Position
Genomictree, Inc. as a current ratio of 17.75, with Debt / Equity ratio of 2.06%
- Current Ratio
- 17.75
- Quick Ratio
- 17.69
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 1.36
- Interest Coverage Ratio
- -33.42
Taxes
In the past 12 months, Genomictree, Inc. has paid 11.47M in taxes.
- Income Tax
- 11.47M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Genomictree, Inc. EV to EBITDA ratio is -70.65, with an EV/FCF ratio of -43.86.
- EV to Sales
- 133.02
- EV to EBITDA
- -70.65
- EV to Free Cash Flow
- -43.86
- EV to Operating Cash Flow
- -57.82
Balance Sheet
Genomictree, Inc. has KRW 75.39B in cash and marketable securities with KRW 55.19M in debt, giving a net cash position of KRW 75.33B billion.
- Cash & Marketable Securities
- KRW 75.39B
- Total Debt
- KRW 55.19M
- Net Cash
- KRW 75.33B
- Net Cash Per Share
- KRW 3,030.27
- Tangible Book Value Per Share
- KRW 5,025.50
Margins
Gross margin is 9.58%, with operating margin of -277.10%, and net profit margin of -209.77%.
- Gross Margin
- 9.58%
- Operating Margin
- -277.10%
- Pretax Margin
- -213.27%
- Net Profit Margin
- -209.77%
- EBITDA Margin
- -188.28%
- EBIT Margin
- -210.54%
Analyst Forecast
The average price target for Genomictree, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -17.13%
- EPS Growth Forecast
- 1.63%
Scores
- Smart Score
- ―
- AI Score
- 44